ArticleBMC nephrology2026
Comparison of intravenous hydration and oral hydration in preventing contrast-induced nephropathy among patients undergoing peripheral vascular interventions.
Article in BMC nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundHydration therapy is recommended to prevent contrast-induced nephropathy (CIN); however, it has not been adequately studied in patients with peripheral vascular disease (PVD) undergoing peripheral vascular intervention (PVI). This study aimed to evaluate the efficacy and safety of intravenous hydration and oral hydration protocols for preventing CIN.
methodsThis quasi-experimental study enrolled patients with PVD who were undergoing PVI from September 2023 to October 2024. Patients were divided into an intravenous hydration group (receiving normal saline at a rate of 1–3 mL/kg/h for 6 h after PVI) or an oral hydration group (receiving 1000 mL of water within the first 3 h and a total of 2000 mL within 24 h after PVI). The primary endpoint was the incidence of CIN, defined as an absolute increase in serum creatinine of more than 26.5 µmol/L within 48 h. The secondary outcomes included renal function indicators (serum creatinine, blood urea nitrogen, and serum uric acid) at 48 h post-surgery; the incidence of adverse reactions (gastrointestinal adverse reactions, infusion-related adverse reactions, and electrolyte imbalances) within 24 h; and the incidence of major adverse events (acute kidney injury stage 3, acute heart failure, and all-cause mortality) during hospitalization and within 7 days after discharge.
resultsA total of 560 patients with PVD were enrolled in the study. The overall incidence of CIN was 3.93% (22/560), with 3.60% (10/278) in the intravenous hydration group and 4.26% (12/282) in the oral hydration group, showing no statistically significant difference (p > 0.05). No statistically significant differences were observed between the two groups in the 48-hour postoperative levels of serum creatinine, blood urea nitrogen, or serum uric acid (p > 0.05). Five patients in the IV hydration group developed non-thrombotic phlebitis, and 3 patients in the oral hydration group experienced gastrointestinal adverse reactions, including nausea (n = 2) and vomiting (n = 1). None of the patients experienced electrolyte imbalances or major adverse events.
conclusionsFor patients with PVD undergoing PVI, both the intravenous hydration and oral hydration protocols used in this study were effective and safe in preventing CIN. These findings support the feasibility of oral hydration as a non-inferior alternative in eligible patients, potentially enhancing patient comfort and reducing clinical burden.
trial registrationThis study was registered in the Chinese Clinical Trial Registry (ChiCTR2400088759, 26 August 2024).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.